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Purpose: This study was undertaken to explore the response rate of
a first-line, three-drug regimen that consisted of bortezomib, pacli-
taxel, and carboplatin in patients with metastatic adenocarcinoma of
the esophagus, gastroesophageal junction, or gastric cardia.
Patients and Methods: Patients with the above diagnosis and
acceptable organ function were treated intravenously on a 21-day
cycle with the following: bortezomib 1.2 mg/m2 on days 1, 4, and 8;
paclitaxel 175 mg/m2 on day 2; and carboplatin with an area under
the curve of 6 on day 2. Patients received indefinite treatment unless
they manifested tumor progression or severe adverse events. All were
monitored for tumor response as well as other clinical outcomes.
Results: The cohort included 35 eligible patients with a median age
of 59 years (range, 36–78) and an Eastern Cooperative Oncology
Group performance score of 0, 1, and 2 in 60%, 34%, and 6% of
patients, respectively. Although this regimen was well tolerated, the
tumor response rate was lower than that anticipated at 23% (95%
confidence interval: 10%, 40%), thereby prompting premature study
closure. There were no complete responses. The median survival for
the cohort was 8.9 months (95% confidence interval: 5.9, 12.8).
Conclusion: As prescribed in this trial and for this indication, this
regimen does not merit further testing.
(J Thorac Oncol. 2008;3: 516–520)
Bortezomib is a modified dipeptidyl boronic acid thatinhibits the 26S proteasome and, in turn, leads to chaos
within the ubiquitin proteasome pathway.1 The latter is crit-
ical to cell protein regulation, and plays a key role in the
degradation of damaged or senescent proteins. In the setting
of cancer, bortzomib’s effects on the 26S proteasome result in
altered protein homeostasis and disruption of cell signaling
pathways, thereby detracting from the cancer cell’s ability to
remain viable.1 Indeed, proof of concept has already been
established: bortezomib provides a survival advantage to
chemotherapy-refractory multiple myeloma patients, and this
drug is the first such class of agents approved by the Food and
Drug Administration for a cancer indication.2,3
This study therefore sought to determine the response
rate of a three-drug regimen that included bortezomib in
patients with metastatic cancer of the esophageal cancer,
gastroesophageal junction, and gastric cardia, herein referred
to as “esophageal cancer.” This issue is relevant for several
reasons. First, esophageal cancer cells do also rely on an
intricate cell signaling system, and it is plausible that protea-
some inhibition might disrupt one or more of these pathways
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and thereby result in the death of esophageal cancer cells.4
Pathways involving such mediators as NF kappa B, BAX,
and P27 have been implicated in therapy resistance in esoph-
ageal cancer, and they are targets of bortezomib.5 Second,
preclinical data suggest that bortezomib carries antineoplastic
activity in this setting. Fujita and others examined the gastric
cancer cells lines AZ521, MKN45, and NUGC3 and observed
that exposure to bortezomib resulted in cell growth inhibi-
tion.6 Synergy occurred when bortezomib was combined with
a conventional chemotherapy agent, such as paclitaxel, pre-
sumably from greater down-regulation of NF kappa B and
increasing certain cell cycle regulatory proteins.5 Although
this study focused on gastric cancer cell lines, not esophageal,
the adjacency of these two organs coupled with established
similar treatment approaches suggest that these data are in
fact relevant even to the latter. Third, favorable, mounting
clinical evidence in patients with other solid tumor malignan-
cies suggests that this agent merits further study in patients
with esophageal cancer.7–9 Ocean and others treated 36 gas-
tric cancer patients with bortezomib alone versus bortezomib
plus irinotecan.7 The latter regimen yielded a 44% response
rate, and the former a 9% response rate. These findings led
these investigators to conclude that bortezomib is “active” in
patients with metastatic gastric cancer. Hence, the foregoing
suggests a rationale for further testing bortezomib in patients
with metastatic esophageal cancer.
Thus, the present study was undertaken. The study team
used a phase II study design to test a three-drug regimen of
bortezomib, paclitaxel, and carboplatin. This three-drug reg-
imen was chosen based on the following three factors that
summarize rationale and feasibility: (1) the preclinical and
clinical synergistic antitumor effects, as described earlier; (2)
the fact that the regimen paclitaxel and carboplatin has
demonstrated antineoplastic activity in this setting10–12; and
(3) the fact that Ma et al.5 had generated the prerequisite
phase I data for the appropriate dosing of this combination.
These phase I data defined the optimal dosing of all three of
these agents based on sequencing of bortezomib with respect
to chemotherapy and dose-escalation of both bortezomib and
paclitaxel.
PATIENTS AND METHODS
Overview. This phase II study was designed and con-
ducted within the North Central Cancer Treatment Group,
and the Institutional Review Boards at each study site had
approved the study protocol. All patients were required to
provide written consent before enrollment.
Eligibility. Eligibility criteria consisted of the following: (1)
patient age of18 years; (2) histologic or cytologic evidence of
adenocarcinoma of the esophagus, esophagogastric junction,
or gastric cardia; (3) no curative therapeutic options; (4)
measurable disease, as defined by the RECIST criteria13; (5)
Eastern Cooperative Oncology Group performance status of 2
or better; (6) a negative pregnancy test 7 days before regis-
tration or earlier; and (7) patient’s estimated life expectancy
of 12 weeks or longer.
In addition, all patients had to have had the following
laboratory parameters within 14 days before registration: (1)
absolute neutrophil counts 1.5  103 cells/mL; (2) platelet
count 100  103 cells/mL; (3) total bilirubin equal to or
below the upper limit of normal; (4) aspartate aminotransfer-
ase 3 times the upper limit of normal; (5) the alkaline
phosphatase 2 times the upper limit of normal; and (6)
serum creatinine 1.5 times the upper limit of normal.
Patients were not allowed to enter the trial in the event
of any one of the following: (1) pregnant, nursing, or of
child-bearing potential and unwilling to use effective contra-
ception; (2) previous radiation to greater than 25% of the
marrow cavity; (3) open abdominal surgery in the previous 4
weeks or a laparoscopic procedure within the previous 2
weeks; (4) an uncontrolled infection or a chronic debilitating
illness; (5) known central nervous system metastases; (6)
peripheral neuropathy of grade 2 or worse; (7) a previous
allergic reaction to either carboplatin or paclitaxel; (8) a prior
malignancy, except for adequately treated basal cell or squa-
mous cell carcinoma of the skin or any other cancer for which
the patient has been cancer-free for 5 years or longer; or (9)
prior chemotherapy, radiation, immunotherapy, or biologic
therapy for recurrent or metastatic disease. For clarification,
prior radiotherapy and/or chemotherapy was permissible if
administered in the neoadjuvant or adjuvant setting after
complete resection of the original tumor. Moreover, previous
combination chemotherapy and radiation for locally ad-
vanced disease given with curative intent were also permis-
sible if a complete clinical or pathologic response had been
achieved with this therapy and if the last chemotherapy or
radiation was 6 months before enrollment.
Pretreatment Evaluation. All patients underwent a history
and physical examination, which included a brief neurologic
examination, within 14 days of study registration. In addition,
a hemogram, a total bilirubin, a serum creatinine, an alkaline
phosphatase, an aspartate aminotransferase, and a chest ra-
diograph were also obtained. A computerized tomography
scan or a magnetic resonance imaging study that included a
site of measurable tumor was required within 30 days of
study registration.
Treatment. Patients were treated with bortezomib 1.2
mg/m2 intravenously on days 1, 4, and 8 of a 21-day chemo-
therapy cycle. Additionally, paclitaxel 175 mg/m2 was ad-
ministered intravenously over 3 hours on day 2. Finally,
carboplatin with an area under the curve (AUC) of 6 was also
administered intravenously on day 2. The protocol specified
appropriate premedication with dexamethasone, diphenhy-
dramine, and ranitidine or an equivalent medication in an
effort to prevent drug reactions.
Patients were to continue on the regimen indefinitely,
until cancer progression, or until unacceptable toxicity oc-
curred. The patient’s decision to stop therapy with no appar-
ent explanation was also considered acceptable and was
specified in the protocol.
Dose modifications were specified for each agent. For
bortezomib, an interval absolute neutrophil count of less than
1.0  103 cells/mL and/or a platelet count of less than 50 
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103 cells/mL required that this agent be omitted on day #8
and then reduced by 20% for subsequent cycles. A similar
approach was specified in the event of febrile neutropenia,
defined as the above neutrophil count with a concurrent fever.
Similarly, the above parameters at any point during a treat-
ment cycle prompted a 20% dose reduction of both paclitaxel
and carboplatin. Grade 3 or worse gastrointestinal toxicity or
other nonhematologic toxicity also required dose reductions
for both these drugs. Finally, at the beginning of each treat-
ment cycle, all cancer treatment was to be held until the
absolute neutrophil count and platelet count exceeded 1.5 
103 cells/mL and 100  103 cells/mL, respectively. Treat-
ment was also to be held in the event of grade 3 or worse
nonhematologic toxicity with resumption of chemotherapy
when toxicities either returned to baseline or dropped to less
than grade 1. Patients with grade 2 neuropathy could proceed
with chemotherapy with a 20% dose reduction of all three
drugs, but patients with neuropathy of grade 3 or worse were
to discontinue treatment on protocol. In the event that che-
motherapy needed to be held for more than 3 weeks, patients
were again to discontinue treatment on protocol.
The protocol stated that full supportive care measures
were to be used while patients received chemotherapy on
study. The use of blood products, antibiotics, nutrition sup-
port, and antiemetics were allowed as clinically appropriate.
The use of neutrophil growth factor support was allowed in
the event of severe neutropenic complications.
Follow-up Evaluations. Visits with an oncologist were
required every 3 weeks, but patients were otherwise moni-
tored with a weekly hemogram and other weekly blood
testing as deemed clinically appropriate by their healthcare
providers. Tumor measurements were to be obtained imme-
diately before the anticipated third cycle, and every other
cycle thereafter unless more frequent assessments were re-
quired to confirm a tumor response. RECIST criteria were
used to define a confirmed tumor response.13 Adverse events
were recorded with the National Cancer Institute’s Common
Toxicity Criteria, version 3.0 and tracked throughout the
study period.
Statistical Analyses. The primary objective of this trial was to
assess the proportion of patients with a confirmed tumor
response treated as per the regimen outlined in this protocol.
The largest success proportion whereby the proposed treat-
ment regimen would be considered unworthy of further study
was 30%, based on earlier data that tested carboplatin and
paclitaxel alone, and the smallest success proportion that
would warrant further study was 50%. These parameters were
conservative based on previously reported response rates with
carboplatin and paclitaxel in similar settings.8–10 A one-stage
Fleming design with a minimum of 25 patients and a maxi-
mum of 60 patients were to be accrued.14 If 8 or fewer
confirmed responses were observed in the first 25 patients, it
was thought appropriate to terminate the study. Accrual was
not terminated during the interim analysis. A confidence
interval for the percentage of patients with a confirmed
response was calculated using the exact binomial method.
Secondary endpoints included descriptive summaries
of time-to-cancer progression, adverse events, and overall
survival. Time-to-cancer progression is the time from enroll-
ment on study to the time of evidence of cancer progression.
Adverse events are presented in part in tabular form. Overall
survival is defined as the time from study registration to death
from any cause. Time-to-event distributions are estimated
with the Kaplan Meier method.15
RESULTS
Demographics. Thirty-five eligible patients were enrolled
and treated between November 2005 and June 2006. One
patient cancelled and did not receive any of the drugs, and
another was subsequently found to be ineligible; thus, these
two patients are not included in the tumor response and
survival analyses shown below. The median age of this
35-patient cohort at study entry was 59 years with a range
from 36 to 78 years. Eleven percent were women. Eastern
Cooperative Oncology Group performance scores of 0, 1, and
2 were observed in 60%, 34%, and 6% of the cohort,
respectively (Table 1).
Treatment Administration. Patients completed a median of
four cycles of chemotherapy (range, 1–13). Reasons for
discontinuation are as follows: cancer progression (n  23),
adverse events or patient declined further,10 or other.3
Although intermittent dose reductions were required for
medical reasons, most patients nonetheless received the ma-
jority of the originally intended chemotherapy dosing. For
bortezomib, the range of the median percentage of targeted
dose prescribed was 67 to 100% over the first 6 cycles of
chemotherapy; and, for paclitaxel, it was 72 to 100%. For
carboplatin, the percentage of patients who maintained an
AUC of 6 over the first 6 cycles ranged from 7% for cycle 6
to 100% for cycle 1 (median 45%). For the first 3 cycles, the
TABLE 1. Baseline Characteristics (n  35)
Patient (%)a

















a Unless otherwise specified.
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majority of patients did receive carboplatin at an AUC of 6.
During the first 2 cycles of therapy, 17 patients (47%)
received approximately the full dose of all 3 drugs.
Response, Progression, and Survival Data. At the time of
this report, within this 35-patient cohort, eight patients had
manifested a confirmed partial tumor response, thus provid-
ing a response rate of 23% (95% confidence interval: 10%,
40%). There were no complete responses. The median dura-
tion of response was 4.7 months (95% confidence interval:
2.8, 9.0).
The median survival for the cohort was 8.9 months
(95% confidence interval: 5.9, 12.8) (Figure 1). The median
time-to-cancer progression was 4.2 months (95% confidence
interval: 2.5, 5.1) (Figure 2). At the time of this report, 97%
of patients have shown evidence of cancer progression, and
86% have died. For the five patients who remain alive, the
median follow-up has been 16.8 months (range, 14.7, 21.6).
Adverse Events. Adverse event data pertain to all 36 pa-
tients who received any study drug; the one ineligible patient
is included. Only grade 2 or worse events are reported. Of the
36 patients treated on this trial, all suffered at least one grade
3 or worse event, and 25 (69%) suffered at least one grade 4
event. Grade 3 events included the following: neutropenia
(22%), thrombocytopenia (25%), vomiting (14%), diarrhea
(17%), neurologic symptoms (22%), and fatigue (17%) with
parenthetical percentages referring to the percentage of pa-
tients who sustained at least one such event. Grade 4 events
included primarily neutropenia (58%). There were no grade 5
events (Table 2).
DISCUSSION
This study was undertaken to explore the role of a
three-drug regimen that included bortezomib in patients with
metastatic esophageal cancer. The agents bortezomib, pacli-
taxel, and carboplatin were tested for this purpose. The tumor
response rate of 23% (95% confidence interval: 10%, 40%)
was well below the anticipated threshold to suggest promise,
and the study was therefore terminated prematurely. In effect,
previously reported tumor response rates in the range of 43%
with paclitaxel and carboplatin alone were not observed in the
present study.8
One might argue that an end point, other than tumor
response rate, should have been used in this trial, particularly
because bortezomib may exert only static effects. In reply, it
is important to point out that other outcome data from this
study also did not suggest that bortezomib was providing
clinical benefit. The median survival in previous studies that
evaluated the doublet of paclitaxel and carboplatin was 9
months8; and, in the present study, it was 8.9 months—
roughly comparable. Thus, based on these overall survival
data, this three-drug combination does not appear to be
providing a favorable clinical impact over and above what
would be expected from paclitaxel and carboplatin alone.
This finding underscores the need to evaluate other regimens
for the treatment of patients with metastatic cancer of the
esophagus, stomach, and gastroesophageal junction.
FIGURE 1. The median survival for the cohort was 8.9
months (95% confidence interval: 5.9, 12.8 months).
FIGURE 2. The median time-to-cancer progression for the
cohort was 4.2 months (95% confidence interval: 2.5, 5.1
month).
TABLE 2. Maximum Severity Adverse Eventsa
Patients (%)b (N  36)
Grade 2 Grade 3 Grade 4
Hematologic
Neutropenia 1 (3) 8 (22) 21 (58)
Thrombocytopenia 5 (14) 9 (25) 0
Anemia 6 (17) 0 1 (3)
Gastrointestinal
Nausea 13 (36) 3 (8) 0
Vomiting 7 (19) 5 (14) 0
Diarrhea 4 (11) 6 (17) 0
Abdominal pain 1 (3) 2 (6) 0
Other
Infection 0 2 (6) 0
Hyponatremia 0 2 (6) 0
Neurologic 9 (25) 8 (22) 0
Myalgias 4 (11) 3 (8) 0
Dyspnea or evidence of hypoxia 4 (11) 0 1 (3)
Pleural effusion 0 0 1 (3)
Fatigue 13 (36) 6 (17) 0
Dehydration 1 (3) 2 (6) 0
a Grade 1 events are not reported.
b If a patient experienced repeated events of the same severity, only one is counted.
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